Pharmaceuticals

Hot topics of 2024 will smoulder into new year

19 Dec 2024

Inflation in the United States, a struggling Chinese economy and Boeing’s existential challenges were among the stories that dominated this year. In this Viewsroom podcast, Breakingviews columnists explain why these issues – among others – will keep cropping up in 2025.

Obesity giants will begin $80 bln M&A face-off

17 Dec 2024

Eli Lilly and Novo Nordisk will need to invest the war chests they are amassing from sales of weight-loss drugs. They could snap up rivals like Zealand Pharma, or forge into new areas, say by buying autoimmune player Argenx. Pressure to do deals raises the risk of overpaying.

AstraZeneca lacks good medicine for Chinese limbo

13 Dec 2024

Executives at the $205 bln drugmaker have been detained by Beijing, hitting its shares. One way for CEO Pascal Soriot to ringfence China risk from the rest of AstraZeneca might be to list or spin off the unit. Yet that might just highlight fresh reasons to mark down the stock.

Walgreens invites a Rube Goldberg buyout plan

12 Dec 2024

The flailing $8 bln drugstore would be a cheap target were it not for a $36 bln morass of debt, long-term leases and opioid liabilities. Yet a ruthless buyer could lean on cutting rents, chairman Stefano Pessina’s 17% stake and sellable bits to excavate whatever is left to save.

Drugmakers brace for US political side effects

5 Dec 2024

Donald Trump’s health agency nominee, Robert Kennedy, brings dangerous views on vaccines as well as skepticism about sky-high medicine prices. In this week’s Viewsroom, Breakingviews columnists discuss the impact on giants like Novo Nordisk and how other countries might react.

European pharma’s growth prescription: pivot to US

28 Nov 2024

Novartis, Novo Nordisk and regional rivals lost $86 bln in value over concerns about tariffs and other possible measures by President-elect Donald Trump. Stateside M&A and manufacturing moves could ease the pain and boost revenue. But hopping across the pond will mean paying up.

Brookfield has room to sweeten Spanish drug deal

20 Nov 2024

Grifols rejected a 6.5 billion euro offer from the Canadian firm and its founder family. That’s not surprising, given the offer is far from generous and the pharma company’s sales are recovering. Bruce Flatt’s group can afford to pay more and still clear an acceptable return.

Vaccine makers exposed to political pathogen

7 Nov 2024

President-elect Donald Trump wants Robert Kennedy to ‘run wild’ on public health policy. Details, as usual, are sketchy, and it may be hard to put the anti-jab activist in an official administration role. Even with him as a senior adviser, though, Moderna and GSK lack immunity.

Lilly’s weight loss let-down is all about timing

30 Oct 2024

The obesity drug maker shed $50 bln of market value after sales disappointed the assumption that rising supply would meet endless demand. It may be a blip due to slow marketing. But a valuation triple industry norms leaves Eli Lilly no room to fumble its window to extract value.

Sanofi sale is critical health check for mega LBOs

10 Oct 2024

The French pharma company is deciding whether to sell its consumer drugs unit to Clayton Dubilier & Rice or PAI for $17 bln, says Bloomberg. It helps that volatile equity markets make an alternative listing riskier. A successful deal could give large buyouts a shot in the arm.

Pfizer’s M&A disease brings activist cure

7 Oct 2024

The pharma giant generated over $30 bln of extra cash during the pandemic, then spent over twice as much on questionable deals. With shareholders sitting on a loss under CEO Albert Bourla, Starboard will push for a return to former CEO Ian Read’s parsimony.

CVS surgery would provide little if any relief

1 Oct 2024

As part of a strategic shakeup, the healthcare supermarket may try amputation. A $90 bln acquisition binge has left it indebted and worth less than $80 bln. The breakup math is flimsy, meaning the prescription for boss Karen Lynch is to stop buying and nurse the existing parts.

Copycat drugmakers will be low-key obesity winners

25 Sep 2024

Sandoz and other generic drugmakers are preparing to make cheap versions of Novo Nordisk’s weight-loss drugs. They could grab a large chunk of a potentially $150 bln market. Unlike the Danish group and peer Eli Lilly, their valuations do not yet reflect the potential opportunity.

Big Pharma lacks motive to prep for new pandemics

10 Sep 2024

The WHO warned the next outbreak may be 20 times more deadly than Covid-19. Moderna’s Corona surge should encourage drugmakers to build up vaccine units for the next virus. But with investors giving little credit for one-off jabs, there’s not much incentive to invest.

Mpox drugmaker’s shares may provide false comfort

16 Aug 2024

Bavarian Nordic, which makes a vaccine for the virus, gained $1 bln in value over the past week as the disease spread beyond Africa. The increase is equivalent to several million extra doses. That view, which implies a contained outbreak, may be too benign if mpox keeps mutating.

L’Oréal’s tardy skin care facelift may backfire

5 Aug 2024

After sitting out its IPO, the cosmetics giant is buying 10% of $19 bln dermatology specialist Galderma, which it sold in 2014. The Swiss firm’s fast-growing injectable business is attractive. Yet the move risks making a potential full takeover overly expensive.

Novo Nordisk obesity feast no longer a free lunch

18 Jul 2024

The $603 bln drug group’s shares have more than trebled since 2021 on the back of booming sales of weight-loss treatment Wegovy. To justify that, it will need to keep coming up with new, even better products, and fend off rivals like Pfizer. Neither looks certain.

Drugmaker’s US listing journey starts with failure

9 Jul 2024

Shares in $2 bln Indivior, which in June switched its primary venue from London to New York, fell 42% after flagging slower opioid-treatment sales. Investors may fear that CEO Mark Crossley took his eye off the ball. With little broker coverage, it risks becoming an orphan stock.

Smith & Nephew faces long and painful activist fix

4 Jul 2024

Cevian has taken a 5% stake in the $11 bln underperforming London-listed medical equipment maker. Curing its depressed share price will require deep operational surgery. While that may take time, a breakup could be a second treatment further down the line.

Moderna stock is lone omen of bird flu pandemic

17 Jun 2024

The $56 bln Covid vaccine maker’s stock is up 40% since March after an avian flu outbreak. A new jab might be worth trillions for society. The uncertainty about another pestilence, however, means its value to Moderna is probably less than what investors have already gained.